Your browser doesn't support javascript.
loading
Formulation, Standardization, and a Preliminary Before-After Clinical Trial on Effect of a Traditional Herbal Formula (Maqliasa) on Manifestations of Ulcerative Colitis.
Shirzad, Meysam; Ahmadian-Attari, Mohammad Mahdi; Ghafoori, Seyed Mohammad Sadegh; Kashani, Leila Mohammad Taghizadeh; Pasalar, Mehdi; Abbassian, Alireza; Agah, Shahram.
Affiliation
  • Shirzad M; Department of Persian Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Ahmadian-Attari MM; Evidence-Based Phytotherapy and Complementary Medicine Research Center, Alborz University of Medical Sciences, Karaj, Iran.
  • Ghafoori SMS; Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Kashani LMT; Department of Traditional Medicine, Medicinal Plants Research Center of Barij, Kashan, Iran.
  • Pasalar M; Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Abbassian A; Department of Persian Medicine, School of Traditional Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Agah S; Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran.
Curr Drug Discov Technol ; 18(1): 113-119, 2021.
Article de En | MEDLINE | ID: mdl-31985380
ABSTRACT

BACKGROUND:

Ulcerative Colitis (UC) is a chronic condition that represents a group of intestinal disorders causing prolonged inflammation of the digestive tract. Nowadays, efforts to investigate new remedies have led to a committed movement toward the integration of traditional and complementary medicine into mainstream medicine. In Traditional Persian Medicine (TPM), Maqliasa is one of the most frequent gastrointestinal prescriptions which is claimed to be effective in both remission and recurrent phases of UC.

OBJECTIVE:

The aim of this pilot study was to examine the effect of Maqliasa on UC symptoms.

METHODS:

Through a non-randomized before-after uncontrolled clinical trial, 13 outpatients with active UC were enrolled in the study. They continued their conventional drug regimens plus Maqliasa capsules (2 capsules t.i.d.) for 28 days. Three visits were arranged for each patient- the first admission, day 14th admission and day 28th admission. The patients were evaluated by Lichtiger Colitis Activity Index. Wilcoxon signed-rank test was used for statistical analysis.

RESULTS:

The Lichtiger colitis activity index improved in the study group was compared to the corresponding baseline values baseline score 7.8 ± 0.5; after two weeks 5.9 ± 0.6 (P=0.002); after four weeks 3.6 ± 0.5 (P=0.001).

CONCLUSIONS:

This study showed the promising effect of Maqliasa in the treatment of active UC. However, due to some of the limitations of the study, conducting future high-quality randomized clinical trials would be crucial.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Rectocolite hémorragique / Préparations à base de plantes / Préparation de médicament Type d'étude: Clinical_trials / Diagnostic_studies Limites: Humans Pays/Région comme sujet: Asia Langue: En Journal: Curr Drug Discov Technol Sujet du journal: FARMACOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Iran

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Rectocolite hémorragique / Préparations à base de plantes / Préparation de médicament Type d'étude: Clinical_trials / Diagnostic_studies Limites: Humans Pays/Région comme sujet: Asia Langue: En Journal: Curr Drug Discov Technol Sujet du journal: FARMACOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Iran
...